Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E. Ahn, Matthew S. Davids, Alvaro J. Alencar et al.|Blood Advances|2024Cited by 12
SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.Jennifer L. Crombie, Matthew S. Davids, Inhye E. Ahn et al.|Journal of Clinical Oncology|2023Cited by 2
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)Inhye E. Ahn, Matthew S. Davids, Danielle M. Brander et al.|Hematological Oncology|2023Cited by 1
212 | SAVE (SAFE ACCELERATED VENETOCLAX ESCALATION): RESULTS OF A PROSPECTIVE, PHASE Ib STUDY OF VENETOCLAX WITH AN ACCELERATED DOSE RAMP‐UP IN PATIENTS WITH CLLJennifer L. Crombie, Matthew S. Davids, Il Young Ahn et al.|Hematological Oncology|2025Cited by 0